In the acute promyelocytic leukemia (APL) bearing the t(15;17), all-trans-retinoic acid (ATRA) treatment induces granulocytic maturation and complete remission of leukemia. We identified miR-342 as one of the microRNAs (miRNAs) upregulated by ATRA during APL differentiation. This miRNA emerged as a direct transcriptional target of the critical hematopoietic transcription factors PU.1 and interferon regulatory factor (IRF)-1 and IRF-9. IRF-1 maintains miR-342 at low levels, whereas the binding of PU.1 and IRF-9 in the promoter region following retinoic ATRA-mediated differentiation, upregulates miR-342 expression. Moreover, we showed that enforced expression of miR-342 in APL cells stimulated ATRA-induced differentiation. These data identified miR-342 as a new player in the granulocytic differentiation program activated by ATRA in APL.
Introduction
Acute promyelocytic leukemia (APL) is characterized by chromosomal translocations involving the retinoic acid receptor-a gene that result in clonal expansion of hematopoietic precursors blocked at the promyelocytic stage of differentiation. 1 The treatment of the t(15;17) APL cells with all-transretinoic acid (ATRA) overcomes this block and induces granulocytic differentiation. 2, 3 Mammalian microRNAs (miRNAs) are emerging as key regulators of the development and function of the hematopoietic system. 4 Indeed, several miRNAs are highly expressed in specific hematopoietic lineages and manipulation of their levels has been correlated with changes in cellular properties or differentiation. However, for many of them, the mechanism of their regulation is still not characterized. Furthermore, it has been suggested that miRNAs might be important in the molecular pathogenesis of leukemia interfering with pathways essential for hematopoietic differentiation. 5 miR-342 was previously identified as one of the miRNAs induced by ATRA-induced differentiation of APLs. 6, 7 This miRNA is encoded in an intron of the Enah/Vasp-like (EVL) gene and in human colorectal cancer its expression is repressed by aberrant methylation of the EVL promoter. 8 Furthermore, it was shown that miR-342 reconstitution induced apoptosis in colorectal cancer cell lines. 8 These data suggested that repression of miR-342 expression may promote colorectal cancer formation by enhancing antiapoptotic pathways.
One of the molecular mechanisms mediating ATRA-induced growth inhibition is the increased expression of interferon regulatory factors (IRFs). The IRF proteins are regulators of transcription and regulate IFN and IFN-inducible gene expression. 9 Here, we found that, in ATRA-treated APL cells, interferon regulatory factor (IRF)-1, IRF-9 and PU.1 regulate EVL/miR-342 expression. IRF-1 maintains miR-342 levels in untreated cells, whereas miR-342 upregulation following ATRA treatment, requires binding of IRF-9 and PU.1 in the EVL promoter. Furthermore, we showed that ATRA-mediated miR-342 activation contributes to the granulocytic differentiation of APL cells.
Materials and methods

Reagents
All-trans-retinoic acid was purchased from Sigma (St Louis, MO, USA) and utilized at a concentration of 1 mM unless differently specified.
Oligonucleotides
Oligonucleotides utilized in this work are listed in Supplementary Table S1 .
Cell cultures
NB4 cell line was maintained in RPMI 1640 medium supplemented with 1 Â penicillin/streptomycin solution, 1 Â L-glutamine and 10% fetal bovine serum as previously described. 10 Immunophenotyping and cell death analysis Cell differentiation was evaluated by direct immunofluorescence staining using phycoerythrin (PE) anti-human CD11b (eBiosciences, San Diego, CA, USA) and PE-IgG1 isotype control (eBiosciences). A minimum of 10 000 events were collected for each sample by FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) by using CellFit software (Becton Dickinson) for data acquisition and analysis. Apoptosis was quantified using Cell Death Detection ELISA Kit (Roche Diagnostics Corp., Mannheim, Germany) following the manufacturer's protocol.
miR-342 expression constructs
The pU1-342 plasmid was generated by cloning a fragment of the pri-miR-342 (from À142 to þ 123 bp relative to the 5 0 end of mature miR-342) into the pSP65-U1 cassette plasmid. 11 The expression cassette was then subcloned into the EcoRV site of the lentiviral vector pRRLcPPT.hPGK.EGFP.WPRE. 10 Infective particles were produced and utilized as previously described. 10 
RNA extraction and analysis
Total RNA from cells was extracted using TRIzol RNA isolation system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Northern blot analysis of miRNA was performed as previously described. 10 Specific oligonucleotides were utilized as probes (Supplementary Table S1 ).
Hsa-miR-342 quantification was performed by real-time PCR in ABI PRISM 7900 Sequence Detection System (Applied Biosystems, Warrington, UK). DDC t values were normalized with those obtained from the amplification of the endogenous U6 snRNA.
The EVL transcript was detected with TaqMan oligonucleotides hCG22886 (Applied Biosystems) by real-time PCR in ABI PRISM 7900 Sequence Detection System. DDC t values were normalized with those obtained from the amplification of the endogenous GAPDH) mRNA. Granulocyte colony-stimulating factor receptor (G-CSFr) mRNA quantification was performed with SensiMix dT Kit (Quantase, London, UK), according to the manufacturer's instructions. DDC t values were normalized with those obtained from the amplification of the endogenous GAPDH mRNA with Quantitect Primer Assay (Qiagen, Hilden, Germany). All reactions were performed in triplicate.
Immunoblot analysis
Cells were washed twice in phosphate-buffered saline (PBS) and lysed on ice for 30 min in lysis buffer, containing 50 mM TrisHCl (pH 8), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 1 mM dithiothreitol and protease inhibitor mix (GE Healthcare, IL, USA). Samples were pelleted by centrifugation at 13 000 g for 10 min at 4 1C. The supernatant (whole-cell lysate) was recovered and protein concentrations were determined using a Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Briefly, 80 mg of whole-cell extract was separated by 10% SDS-polyacrylamide gel electrophoresis and electroblotted to nitrocellulose membrane (Protran, S&S, Drammen, Norway); immunoblots were incubated with antibodies to PU.1 (Cell Signaling Technology, Beverly, MA, USA) at a dilution of 1:1000, IRF-1 (sc-497; Santa Cruz Biotechnology) at a dilution of 1:500, IRF-9 (sc-10793; Santa Cruz Biotechnology, Santa Cruz, CA, USA) at a dilution of 1:500 and GAPDH (Abcam, Cambridge, UK) at a dilution of 1:10 000. Immunoreactivity was determined using the ECL method (Pierce, Rockford, IL, USA) with the reagents provided according to the manufacturer's instructions. 5 0 -End mapping of EVL cDNA was performed with the 5 0 RACE System (Invitrogen) using the gene-specific primers for PCR amplification (see Supplementary Table S1 ).
Chromatin Immunoprecipitation assay
DNA/protein crosslinking was obtained by incubating the cells for 20 min at 37 1C in 1% formaldehyde. After sonication, chromatin was immunoprecipitated overnight with 10 ml of anti-PU.1, 15 ml of anti-IRF-1 or 15 ml of anti-IRF-9 antibodies (same as immunoblots). Immuoprecipitation without specific antibody was performed as negative control. After washing, the crosslinks were reversed and the DNA was purified by phenol-chloroform extraction and ethanol precipitation.
Real-time PCRs of the genomic region containing the putative PU.1 and IRF1-binding site were performed in triplicate by using Power SYBR green mater mix (Applied Biosystem) with oligos EVLprom-fw2 and EVLprom-rev1. Cycling parameters were 50 1C 2 min, 95 1C for 10 min, followed by 55-60 cycles of 95 1C for 15 s, 60 1C 1 min. Negative control amplifications were performed on tubulin with oligos Tub up and Tub down. The relative occupancy of the immunoprecipitated factor at a locus was estimated by using the comparative threshold method. 12 
Promoter analysis
The region placed about 900 bp upstream the transcription start site of EVL gene was PCR amplified and cloned upstream of the FF luciferase ORF in pGL3-Basic Vector (Promega, Madison, WI, USA), giving rise to the EVL-prom-wild-type (WT) plasmid. This construct was used as template in a reverse PCR reaction to generate the EVL-prom-mut-IRFs (Mut-IRFs) plasmid, the EVLprom-mut-PU.1 (Mut PU.1) plasmid and the EVL-prom-mut-IRFs-PU.1. Briefly, 10 mg of each pGL3 derivative plasmid (or an empty vector) and 4 mg of control pRL-TK vector were individually transfected by electroporation into NB4 cells. At 12 h posttransfection, half of the cells were treated with ATRA. After 48 h of treatment, cells were harvested and assayed with Dual Luciferase Assay (Promega) according to the manufacturer's instructions.
Results
miR-342 is induced during ATRA-mediated differentiation of APL cells
Acute promyelocytic leukemia cell lines are useful tools for hematopoietic cell lineage differentiation as they respond to ATRA treatment allowing cells to reach a neutrophil granulocyte terminal differentiation.
3,13 miR-342 was recently identified by microarray analysis as one of the microRNAs induced by ATRA treatment in the APL cell line NB4. 6, 7 This miRNA is encoded in the third intron of the EVL gene ( Figure 1a) and it has been suggested to be involved in the activation of apoptotic pathways in colorectal cell lines. 8 Northern blot analysis confirmed that ATRA induced a marked and selective increase of miR-342 in NB4 starting at 24 h after treatment and increasing progressively up to 72 h (Figure 1b) . Interestingly, miR-342 behaves very similarly to miR-223, a miRNA with a defined role in ATRAmediated differentiation of APL and granulopoiesis.
10,14 Similar miR-342 upregulation was found in the HL60 cell line, another ATRA responding leukemia cell line (data not shown). We also analyzed the expression of miR-342 host gene EVL using RQ-PCR (Figure 1c) . Similarly to miR-342, EVL transcript showed increased expression during ATRA treatment. These results indicate that in ATRA-treated NB4 cells, the expression of EVL and miR-342 is co-regulated. Similarly, coordinated expression of miR-342 and its host gene EVL has been also shown in colorectal and multiple myeloma cell lines. 6, 15 Altogether these data indicate that miR-342 and EVL expression is very likely under the control of common regulatory elements.
miR-342 is transcriptionally modulated by IRFs and PU.1
The transcriptional start site for EVL mRNA was identified by 5 0 RACE on RNA purified from NB4 cells (Supplementary Figure S1 ). It mapped 10 bp downstream to the 5 0 end of the EVL transcript (NM_016337) reported in NCBI database. Computational analysis of the EVL promoter region by the Chip-Mapper program 16 identified two binding sites for the transcription factors IRF-1 and IRF-9 (also known as ISGF3g/p48) and one for PU.1 embedded in a region located upstream the transcription start site (Figure 2a ) and highly conserved in mammals (Supplementary Figure S1) . IRF-1 and IRF-9 may recognize similar, if not identical, DNA sequences. 9 Interestingly, all these factors have been previously reported to be induced by ATRA treatment in APL cells. 17, 18 The protein levels of these factors were analyzed during ATRA treatment of NB4 (Figure 2b ). IRF-1 and PU.1 proteins are already present in the untreated cells and their levels are induced by ATRA. Moreover, IRF-9 protein is absent in untreated cells and strongly induced by ATRA.
To investigate whether these transcription factors physically interact in vivo with the EVL promoter, we performed a chromatin immunoprecipitation assay on untreated and ATRAtreated NB4 cells (Figure 2c) . DNA from the IRF-1, IRF-9 and PU.1 immunoprecipitates was amplified with a couple of PCR primers located in the promoter region surrounding the putativebinding sites and normalized to the amplification obtained with oligonucleotides corresponding to an unrelated genomic region (tubulin). Immunoprecipitation without specific antibody was utilized as second negative control. Owing to the differences in immunoprecipitation efficiency and in antigene accessibility between different antibodies, it was only possible to compare data obtained from single antibody before and after the ATRA treatment. Figure 2c shows that IRF-1 binding is present at similar levels before and after ATRA administration. Moreover, IRF-9 and PU.1 binding is detected at significant levels only upon ATRA treatment. These results show that IRF-1, IRF-9 and PU.1 bind EVL promoter in vivo in a timely differentiation controlled fashion.
To assess the contribution of individual sites in EVL/miR-342 transcriptional activation, promoter-luciferase fusion constructs containing the WT EVL promoter and site-specific mutants were produced (Figures 2d and e) . After transfection in NB4 cells, half of the culture was treated with ATRA for 48 h and half was maintained without the inducer for the same time. In untreated cells, the mutation in the IRFs-binding motifs (Mut-IRFs) resulted in a drastic decrease of luciferase activity whereas mutation of miR-342 and ATRA-induced differentiation of APL ML De Marchis et al the PU.1-binding site (Mut-PU.1) produced a lower effect on reporter transcription, suggesting that this decrease in luciferase activity is not because of PU.1 activity. When both PU.1 and IRFs-binding sites were mutated (Mut-IRFs-PU.1), the transcriptional activity of the reporter was similar to the Mut-IRFs. These data indicate that the major contribution on EVL/miR-342 transcription in the absence of ATRA is because of IRF-1. Moreover, upon ATRA treatment mutation of the PU.1-binding site resulted in a strong reduction (about 50%) of promoter activity whereas the mutation of IRFs sites produced a lower decrease of the transcriptional activity of the reporter. Notably, the double mutant Mut-IRFs-PU.1 has an additive effect in lowering luciferase activity, suggesting that IRF-9 synergizes with PU.1 in the synthesis of EVL/miR-342 transcripts upon ATRA stimulation. It was not possible to compare luciferase levels between untreated and ATRA-treated cells because the Renilla luciferase gene contains sequences that render its activity responsive to ATRA. 19 Altogether these results indicated that IRF-1 participate in maintaining the expression levels of EVL/miR-342 in the absence of ATRA whereas, following ATRA treatment, EVL/miR-342 activation is mainly because of the binding of IRF-9 and PU.1 in the promoter region.
miR-342 stimulates granulocytic differentiation
The role of miR-342 in granulocytic differentiation was analyzed by lentiviral gene transfer in promyelocytic NB4 cells. Overexpression of miR-342 was accomplished by infecting NB4 cells with a lentiviral vector containing a cassette in which a portion of the pri-miRNA was cloned under the control of U1 snRNA regulatory regions (Lenti-342). miRNA levels were analyzed 4 and 7 days after infection, the miR-342 levels resulted in a three and fivefold increase compared with mock-infected cells, respectively (Figure 3a) . Notably, ectopic expression of miR-342 did not alter the apoptosis rate of NB4 cells compared to the mock-infected cells (Supplementary Figure S2) . Moreover, a specific increase of the mRNA expression for the G-CSFr was observed in cells infected with Lenti-342, whereas no changes for the M-CSFr mRNA were detected (Figure 3b ). The transduced cells were then treated with subpharmacological doses of ATRA (10 and 100 nM) and after 48 h the expression levels of the surface marker for granulocytic cell differentiation CD11b were measured by flow cytometry. Cells overexpressing miR-342 showed a marked increase in CD11b-positive cells compared to the mock-infected cells (Figure 4 ). These data indicated that miR-342 contributes to the ATRA-mediated granulocytic differentiation program of promyelocytic precursors.
Discussion
All-trans-retinoic acid is widely used in the treatment of APL because it can directly inhibit cell proliferation and induce terminal differentiation of leukemic blasts into neutrophil granulocytes.
1,2 A discrete number of miRNAs upregulated upon ATRA treatment of APL cell lines have been already identified by different groups 6, 7, 10 but the mechanism by which ATRA regulates miRNA expression is largely uncharacterized. We previously demonstrated that miR-223 is induced by ATRA treatment of APL through the transcription factor C/EBPa and that miR-223 ectopic expression in APL was able to promote granulocytic maturation. 10 In the present work, we have continued our analysis to further characterize miRNAs induced by ATRA and the molecular events responsible for miRNA expression during APL differentiation. We have identified miR-342 as one of the miRNAs specifically induced in APL cell lines. This miRNA is encoded in the third intron of the EVL gene and both genes show coordinated expression. 8, 15 Bioinformatic analysis identified binding sites for IRF-1, IRF-9 and PU.1 in the EVL promoter. These factors are induced by ATRA and we showed that they regulate EVL/miR-342 transcription. In particular, IRF-1 participates in EVL/miR-342 expression before ATRA treatment, whereas IRF-9 and PU.1 are mainly responsible for its induction during ATRA-mediated differentiation.
PU.1 plays a crucial role in myeloid differentiation 20 and its expression is inhibited in t(15;17) APL. PU.1 is upregulated during treatment of APL with ATRA. Furthermore, it has been shown that ATRA-mediated induction of PU.1 expression is critical for differentiation of APL cells carrying the t (15;17) . 18 IRF-1 and IRF-9 has been identified in the context of host defense against viral infections. However, these factors have been shown to modulate not only the cellular response to IFNs and viral infection, but also cell growth, susceptibility to transformation by oncogenes, induction of apoptosis and development of the immune response. 9 In various cancer cells, including those derived from APL, ATRA induces directly the expression of these two transcription factors. 9 Recent evidence suggests that inactivation of the IRF-1 gene may be a critical step in the development of some human leukemias. 21 Furthermore, mice devoid of IRF-1 showed impaired myelopoiesis, suggesting a role for this factor also in normal hematopoiesis. 22 miR-342 expression is not restricted to hematopoietic tissues. 8 In human colorectal cancer, miR-342 expression is repressed by aberrant methylation of the EVL promoter and miR-342 reconstitution induced apoptosis in colorectal cancer cell lines. 8 Indeed, it has been suggested that repression of miR-342 expression may promote colorectal cancer formation by enhancing antiapoptotic pathways. 8 However, ectopic expression of miR-342 in NB4 cells had no effect on cell apoptosis and instead stimulated granulocytic differentiation. This difference might be because of repression of different target mRNAs by the same miRNA or different effects of the same target repression in different cell types. Therefore, much more work will be necessary to identify miR-342 mRNA targets and assign specific functions to miR-342 in different cell lineages.
In conclusion, we identified a new molecular network consisting of miR-342, the IRF-1 and IRF-9 proteins, and the master hematopoietic transcription factor PU.1 involved the granulocytic differentiation of APL mediated by ATRA.
Conclusions
Complete clinical remission with ATRA alone is always transient as RA resistance develops in the treated patients. Modulation of APL differentiation by miRNAs may provide an important tool in leukemia therapy especially for patients with acquired resistance to pharmacological therapies.
